Generic matrix for control nucleic acids

US9920354B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9920354-B2
Application numberUS-201113328280-A
CountryUS
Kind codeB2
Filing dateDec 16, 2011
Priority dateDec 17, 2010
Publication dateMar 20, 2018
Grant dateMar 20, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is in the field of in-vitro diagnostics. Within this field, it provides the amplification of at least a first target nucleic acid that may be present in at least one fluid sample using an internal control nucleic acid for qualitative and/or quantitative purposes and at least one external control nucleic acid in an aqueous buffer. It further provides an analytical system comprising an internal control nucleic acid for qualitative and/or quantitative purposes and at least one external control nucleic acid in an aqueous buffer.

First claim

Opening claim text (preview).

What is claimed is: 1. A process for controlled amplification of a target nucleic acid that may be present in a fluid sample, comprising: (a) providing in a vessel an internal control nucleic acid in the fluid sample, (b) providing a solid support material to the vessel for a period of time and under conditions sufficient to permit nucleic acids comprising the target nucleic acid and the internal control nucleic acid to be immobilized on the solid support material, (c) isolating the solid support material from other material present in the vessel in a separation station, (d) purifying the nucleic acids in the separation station and washing the solid support material one or more times with a wash buffer, (e) providing (i) in a first reaction vessel the purified nucleic acids of step (d), wherein the purified nucleic acids comprise the internal control nucleic acid and the target nucleic acid derived from the fluid sample, and (ii) in a second reaction vessel an external control nucleic acid in an aqueous buffer, wherein the aqueous buffer lacks a fluid sample, (f) adding identical amplification reagents to each of the first and second reaction vessels, (g) incubating the first and second reaction vessels under identical conditions sufficient for amplification reactions to occur, and (h) detecting results of the amplification reactions, wherein the results of the amplification reactions are indicative of the presence or absence of amplification of the target nucleic acid, the internal control nucleic acid and the external control nucleic acid wherein the aqueous buffer has a pH between 6.0 and 12.0 and comprises: 1-100 mM Tris, 0.01-1 mM EDTA, 0.005-0.5% (w/v) Sodium Azide, and 1-200 mg/l Poly(rA) RNA. 2. The process of claim 1 , wherein the aqueous buffer has a pH of about 8 and comprises: 10 mM Tris, 0.1 mM EDTA, 0.05% (w/v) Sodium Azide, and 20 mg/l Poly(rA) RNA. 3. The process of claim 1 , wherein a negative control is provided in a third reaction vessel and is subjected to steps (b) through (h). 4. The process of claim 1 , wherein the fluid sample is a clinical sample. 5. The process of claim 1 , further comprising: (i) determining the quantity of the target nucleic acid. 6. The process of claim 1 , wherein the fluid sample comprises blood. 7. The process of claim 1 , wherein the fluid sample comprises blood plasma. 8. The process of claim 1 , wherein the aqueous buffer is free of biological buffers derived from blood. 9. The process of claim 1 , wherein the aqueous buffer is free of biological buffers derived from blood plasma. 10. The process of claim 1 , wherein the second reaction vessel comprises more than one external control nucleic acid.

Assignees

Inventors

Classifications

  • with an internal standard/control · CPC title

  • Viruses associated with AIDS · CPC title

  • Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis · CPC title

  • C12Q1/6806Primary

    Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence) · CPC title

  • with an external standard/control, i.e. control reaction is separated from the test/target reaction · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9920354B2 cover?
The present invention is in the field of in-vitro diagnostics. Within this field, it provides the amplification of at least a first target nucleic acid that may be present in at least one fluid sample using an internal control nucleic acid for qualitative and/or quantitative purposes and at least one external control nucleic acid in an aqueous buffer. It further provides an analytical system co…
Who is the assignee on this patent?
Eickhoff Meike, Russmann Eberhard, Woelfelschneider Andreas, and 2 more
What technology area does this patent fall under?
Primary CPC classification C12Q1/6806. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).